证券代码：603087 证券简称：甘李药业 公告编号：2026-006 甘李药业股份有限公司 2025年年度业绩预增公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 1. 本期业绩预告适用于实现盈利，且净利润与上年同期相比上升50%以上的情形。 2. 甘李药业股份有限公司（以下简称"公司"）预计2025年年度实现归属于母公司所有者的净利润为 11.00亿元到12.00亿元，与上年同期（法定披露数据）相比，将增加4.85亿元到5.85亿元，同比增加 78.96%到95.23%。 3. 公司预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润为7.00亿元至8.00亿元， 与上年同期（法定披露数据）相比，将增加2.70亿元到3.70亿元，同比增加62.63%到85.86%。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1. 经财务部门初步测算，预计2025年年度实现归属于母公司所有者的净利润为11.00亿元到12.00亿元， 与上年同 ...

Core Viewpoint - Hualan Biological has received approval from the National Medical Products Administration for a clinical trial of its recombinant herpes zoster vaccine, marking a significant step towards entering the clinical trial phase for this preventive biological product [1] Group 1 - Hualan Biological's subsidiary, Hualan Biological Vaccine Co., Ltd., has been granted a clinical trial approval notice for the herpes zoster vaccine [1] - The vaccine is classified as a preventive biological product of category 1.3, indicating its intended use for the prevention of herpes zoster [1] - This approval allows the company to officially commence clinical trials for the vaccine [1]

Core Viewpoint - The company is developing a broad-spectrum anti-snake venom antibody using new antibody technology, aiming to create an innovative drug that is universal, has fewer side effects, and is more convenient for use [1] Group 1: Company Development - The company is focused on developing innovative drugs to meet clinical needs in snakebite treatment [1] - The new antibody technology is expected to complement existing anti-snake venom serum, enhancing treatment options [1] - The goal is to improve the company's long-term competitiveness in the field of snakebite diseases [1]

证券日报网讯1月21日，之江生物在互动平台回答投资者提问时表示，公司欧盟销售收入占比相对较 低，目前未在欧盟国家设立子公司，主要通过代理的形式销售。 ...

Core Viewpoint - Kingsray Biotechnology (01548.HK) announced that its associate company, Legend Biotech, has submitted a 6-K form to the U.S. Securities and Exchange Commission, reporting trade sales net revenue of approximately $555 million for CARVYKTI® for the quarter ending December 31, 2025 [1]. Group 1 - The announcement was made on January 21, 2026, after the Hong Kong trading session [1]. - The trade sales net revenue figure is based on information provided by Janssen Biotech, Inc., and has not been independently verified by either Legend or Kingsray [1].

Group 1 - The core point of the article is that Hualan Vaccine has received approval from the National Medical Products Administration for the clinical trial of its recombinant varicella-zoster virus vaccine (CHO cell) [2] Group 2 - The approval signifies a significant step forward for the company in its vaccine development efforts [2] - This development may enhance the company's position in the vaccine market, particularly in the area of shingles prevention [2] - The announcement reflects ongoing regulatory support for vaccine innovation in the industry [2]

证券日报网讯 1月21日，甘李药业发布2025年年度业绩预增公告称，公司预计2025年年度现归属于母公 司所有者的净利润为11.00亿元到12.00亿元，与上年同期（法定披露数据）相比，将增加4.85亿元到5.85 亿元，同比增加78.96%到95.23%。 （文章来源：证券日报） ...

Core Viewpoint - Maiwei Biotech announced the decision to utilize up to 800 million yuan of temporarily idle raised funds for cash management over a 12-month period, with the option for rolling use [1] Group 1: Financial Management - The net amount of raised funds as of June 30, 2025, is approximately 3.303 billion yuan [1] - 48.45% of the raised funds have been invested in antibody industrialization and other projects [1] - The highest single-day investment in cash management over the last 12 months was about 357 million yuan, with a principal amount of 38.77 million yuan yet to be recovered [1]

证券日报网讯1月21日，成大生物在互动平台回答投资者提问时表示，公司始终以开放和审慎的态度， 关注生物医药领域的潜在机遇，并积极探索产业投资与并购整合机会，打造第二增长曲线。 ...

Core Viewpoint - Kingsray Biotechnology (01548) announced that CARVYKTI is projected to generate trade sales net revenue of approximately $555 million for the quarter ending December 31, 2025, based on the collaboration and licensing agreement established with Janssen Biotech, Inc. on December 21, 2017 [1] Group 1 - Kingsray Biotechnology has entered into a collaboration and licensing agreement with Janssen Biotech, Inc. [1] - The projected trade sales net revenue for CARVYKTI is approximately $555 million for the quarter ending December 31, 2025 [1]